MAM
ABUS icon

Meeder Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Meeder Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,499
Closed -$70K – 1093
2021
Q3 		$70K Sell
16,499
-7,168
-30% -$23.9K ﹤0.01% 994
2021
Q2 		$72K Buy
+23,667
New +$73.3K ﹤0.01% 1003
2019
Q4 		– Sell
-5,716
Closed -$9K – 2218
2019
Q3 		$9K Buy
5,716
+4,867
+573% +$8.39K ﹤0.01% 1559
2019
Q2 		$2K Buy
849
+197
+30% +$504 ﹤0.01% 1840
2019
Q1 		$2K Sell
652
-476
-42% -$1.83K ﹤0.01% 1536
2018
Q4 		$3K Sell
1,128
-4,774
-81% -$23.5K ﹤0.01% 1498
2018
Q3 		$57K Buy
+5,902
New +$58.6K ﹤0.01% 755

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

Meeder Asset Management's ABUS Position: Q4 2021 in Review

Meeder Asset Management sold out of Arbutus Biopharma (ABUS) in Q4 2021, closing a stake of 16,499 shares — an estimated $70K sold.

Meeder Asset Management first reported a position in ABUS in Q3 2018 and held it in 7 quarters. The position peaked at $72K in Q2 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

  • Meeder Asset Management reported no remaining Arbutus Biopharma position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 16,499 Arbutus Biopharma shares in Q4 2021, an estimated $70K.
  • Meeder Asset Management first reported a position in Arbutus Biopharma in Q3 2018 and held it in 7 quarters.
  • Meeder Asset Management's Arbutus Biopharma position peaked at $72K in Q2 2021.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.